May Garrett
Overview
Explore the profile of May Garrett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu J, Pennesi E, Bautista F, Garrett M, Fukuhara K, Brivio E, et al.
Clin Pharmacokinet
. 2024 Jun;
63(7):981-997.
PMID: 38907948
Background And Objective: Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults. Pediatric pharmacokinetic data of inotuzumab ozogamicin are lacking. This...
2.
Garrett M, Knight B, Cortes J, Deininger M
Cancer Med
. 2023 Aug;
12(17):17981-17992.
PMID: 37553873
Background: The BELA and BFORE trials compared bosutinib starting doses of 500 mg once daily (QD) and 400 mg QD, respectively, with imatinib in adults with newly diagnosed chronic phase...
3.
Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J
J Pharmacokinet Pharmacodyn
. 2019 Mar;
46(3):211-222.
PMID: 30859374
This population pharmacokinetics analysis evaluated the target-mediated drug disposition of inotuzumab ozogamicin (InO) through an empirical time-dependent clearance (CL) term and identified potential covariates that may be important predictors of...
4.
Garrett M, Taylor T, Mould D, Amantea M, Chen Y, Ingrosso A, et al.
Cancer Chemother Pharmacol
. 2016 Oct;
78(6):1131-1141.
PMID: 27783139
Purpose: Axitinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 1-3, is approved for second-line treatment of advanced renal cell carcinoma. Axitinib is partially metabolized by cytochrome P450...
5.
Chen Y, Rini B, Motzer R, Dutcher J, Rixe O, Wilding G, et al.
Target Oncol
. 2015 Sep;
11(2):229-34.
PMID: 26400730
Background: Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal...
6.
Chen Y, Suzuki A, Tortorici M, Garrett M, LaBadie R, Umeyama Y, et al.
Invest New Drugs
. 2015 Feb;
33(2):521-32.
PMID: 25663295
Axitinib, a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, showed improved progression-free survival over sorafenib in patients previously treated for advanced...
7.
Tortorici M, Cohen E, Pithavala Y, Garrett M, Ruiz-Garcia A, Kim S, et al.
Cancer Chemother Pharmacol
. 2014 Oct;
74(6):1279-89.
PMID: 25336084
Purpose: Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors, showed antitumor activity as a single agent against several solid tumor types in Phase II and III...
8.
Garrett M, Poland B, Brennan M, Hee B, Pithavala Y, Amantea M
Br J Clin Pharmacol
. 2013 Jul;
77(3):480-92.
PMID: 23834452
Aims: Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma....
9.
Chen Y, Tortorici M, Garrett M, Hee B, Klamerus K, Pithavala Y
Clin Pharmacokinet
. 2013 May;
52(9):713-25.
PMID: 23677771
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 that is approved in the US and several other countries for treatment...
10.
Rini B, Garrett M, Poland B, Dutcher J, Rixe O, Wilding G, et al.
J Clin Pharmacol
. 2013 Apr;
53(5):491-504.
PMID: 23553560
Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic...